Randall S Burd1, Joseph D Tobias. 1. Department of Surgery, Children's Hospital at University of Missouri Hospitals and Clinics, Columbia, USA.
Abstract
BACKGROUND: While the use of intravenous ketorolac in infants less than 6 months old has not been previously reported, ketorolac may reduce opioid use and prevent opioid-associated side effects that are frequent in this age group. We reviewed our experience with ketorolac in infants to develop recommendations for using it after abdominal surgery. METHODS: We reviewed the records of 10 infants less than 6 months old who received ketorolac supplemented with morphine and 8 infants who received morphine alone for pain after abdominal surgery. RESULTS: Infants receiving ketorolac required less morphine than infants receiving morphine alone in the first 48 hours after surgery. Four patients receiving ketorolac did not require any supplemental morphine. CONCLUSIONS: Ketorolac reduces the amount of morphine required after abdominal surgery in infants less than 6 months old. The use of ketorolac deserves further study as a method of reducing opioid-associated adverse effects in this patient group.
BACKGROUND: While the use of intravenous ketorolac in infants less than 6 months old has not been previously reported, ketorolac may reduce opioid use and prevent opioid-associated side effects that are frequent in this age group. We reviewed our experience with ketorolac in infants to develop recommendations for using it after abdominal surgery. METHODS: We reviewed the records of 10 infants less than 6 months old who received ketorolac supplemented with morphine and 8 infants who received morphine alone for pain after abdominal surgery. RESULTS:Infants receiving ketorolac required less morphine than infants receiving morphine alone in the first 48 hours after surgery. Four patients receiving ketorolac did not require any supplemental morphine. CONCLUSIONS:Ketorolac reduces the amount of morphine required after abdominal surgery in infants less than 6 months old. The use of ketorolac deserves further study as a method of reducing opioid-associated adverse effects in this patient group.
Authors: Miho Inoue; Christopher A Caldarone; Helena Frndova; Peter N Cox; Shinya Ito; Anna Taddio; Anne-Marie Guerguerian Journal: Intensive Care Med Date: 2009-06-27 Impact factor: 17.440
Authors: Anne M Lynn; Heidi Bradford; Eric D Kantor; Marilee Andrew; Paolo Vicini; Gail D Anderson Journal: Paediatr Anaesth Date: 2010-12-29 Impact factor: 2.556
Authors: Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim Journal: JAMA Surg Date: 2021-01-01 Impact factor: 14.766